CapsoVision, Inc. (CV)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$5.99+0.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
CapsoVision is developing a new AI-assisted colon imaging product. It aims to raise $14 million to fund growth. The company has a partnership with Canon for better sensors. Revenue is expected to grow about 36% next year.
The company is losing money and missed earnings several times. Revenue and profit may stay weak or get worse. The recent stock drop shows investors doubt the turnaround. Raising money may dilute shares and hurt value.
The market expects about 36% revenue growth next year. Our fair value is near $1.49, close to the current price. We see risk in the company’s losses and execution.
Breaks if: Failure to raise $14 million by mid-2026
Breaks if: Partnership with Canon stalls or ends in 2026
Failure to launch CapsoCam Colon with AI by Q3 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is cautious, as the company faces significant challenges while trying to capitalize on its product development and market expansion.
The market seems to be pricing in a level of fragility due to high expectations and an expensive valuation compared to peers. There is an expectations gap, indicating that investors may be anticipating better performance than what has been delivered recently.
Management is making progress on key priorities, but recent financial performance has been below industry peers. There is a high probability of missing earnings expectations, which adds to the uncertainty in the near term.
The future performance of CV hinges on management's ability to deliver on product launches and the overall health of the healthcare sector. Additionally, any changes in guidance or economic conditions could significantly impact investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company expects FDA clearance for AI Highlights by the end of Q3. It also plans to submit CapsoCam Colon Gen 2 for FDA approval in Q4. These developments enhance the outlook for commercial growth. There are no new threats identified that would weaken this positive view.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 36% in FY26
Over the next 1 to 3 years, CV's performance will depend on execution and sector dynamics. Not investment advice.